A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN
← catalyst calendarNCT03745924 · readout in 483 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
60estimated
Sites
30
Countries
Austria, Belgium, Canada +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-04-01 | actual | When the study began enrolling |
| Primary completion | 2027-12-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-15 | estimated | The whole study's end, after follow-up |
| First posted | 2018-11-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Haemophilia B
Intervention
- Drug: Nonacog beta pegol
Primary outcome
what the primary-completion date above is the date OFNumber of Adverse Drug Reactions (ADRs) (FIX inhibitors, allergic reactions, and thromboembolic events)
measured From start of study period (week 0) to end of study period (up to 9 years)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed